KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Work In Process: 2023-2024

Historic Work In Process for Aurinia Pharmaceuticals (AUPH) over the last 2 years, with Dec 2024 value amounting to $36.6 million.

  • Aurinia Pharmaceuticals' Work In Process was N/A to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year change of. This contributed to the annual value of $36.6 million for FY2024, which is 2.01% down from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' Work In Process is $36.6 million, which was down 2.01% from $37.4 million recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year Work In Process high stood at $37.4 million for FY2023, and its period low was $36.6 million during FY2024.
  • Moreover, its 2-year median value for Work In Process was $37.0 million (2023), whereas its average is $37.0 million.
  • Data for Aurinia Pharmaceuticals' Work In Process shows a maximum YoY declined of 2.01% (in 2024) over the last 5 years.
  • Aurinia Pharmaceuticals' Work In Process (Yearly) stood at $37.4 million in 2023, then fell by 2.01% to $36.6 million in 2024.